Rocket Pharmaceuticals, Inc. announced key appointments within Rocket?s existing corporate leadership team are as follows: Kinnari Patel, Pharm.D., MBA, has been appointed President, Head of R&D and Chief Operating Officer. Dr. Patel will be focused on R&D with oversight spanning research through late-stage development and manufacturing. In addition, she will continue in her capacity as COO, driving company operations aimed toward advancing the company?s key strategic priorities.

Jonathan Schwartz, M.D., has been appointed Chief Medical & Gene Therapy Officer, with his remit spanning Research and Discovery as well as Clinical Development. Dr. Schwartz will bring deep and seasoned scientific and clinical thought leadership instrumental in continuing to develop and advance Rocket?s current and future pipeline. Martin Wilson.

J.D., has been appointed General Counsel & Chief Corporate Officer, and will lead Legal, Compliance, and Corporate Development. This evolution creates a newly integrated team aimed at advancing Rocket?s corporate strategy, led by Mr. Wilson?s strong legal and strategic acumen and experience.